Scientists hunt for DNA markers that predict chemo nerve pain
NCT ID NCT02610439
First seen Mar 29, 2026 · Last updated May 09, 2026 · Updated 5 times
Summary
This study analyzes DNA from 575 breast cancer patients who received the chemotherapy drug paclitaxel. Researchers want to find genetic differences that make some people more likely to develop nerve damage (peripheral neuropathy) from treatment. By comparing DNA from those who had severe nerve damage and those who did not, they hope to identify risk markers that could help personalize chemotherapy in the future.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Eastern Cooperative Oncology Group
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.